RU
Pulmonology
Respiforb® Air
Registration certificate:
ЛП-№(010179)-(RG-RU)
INN:
Budesonide + Formoterol
Release form:
Metered Dose Inhaler (MDI)
Therapeutic Area:
Pulmonology
Pharmacotherapeutic Group:
Drugs for the treatment of obstructive respiratory tract diseases; adrenergic agents for inhalation; adrenergic agents in combination with glucocorticoids or other agents other than anticholinergic agents.
Leaflet:
2og1ftc7v64gslqsg05qykrot1ltgrhg.pdf
546kb
Packaging:

Indications:

  • in adults and children from 6 years of age for bronchial asthma insufficiently controlled with low-dose inhaled glucocorticosteroids and short-acting β2-adrenergic agonists when combined treatment with inhaled glucocorticosteroids and long-acting β2-adrenergic agonists is necessary.
  • for the treatment of symptoms in adult patients with chronic obstructive pulmonary disease (COPD) when the specific post-bronchodilatation rate of forced expiratory volume in 1 second (FEV1) is less than 70 % of normal and exacerbations are occurring or have occurred despite regular treatment with bronchodilators.

This product is not included in the Essential Drug List (EDL).

Prescription Status: Rx (prescription) only.

THERE ARE CONTRAINDICATIONS. PLEASE CONSULT A HEALTHCARE PROFESSIONAL BEFORE USE.

For the full medical use instructions of Respiforb® Air (Budesonide + Formoterol), metered-dose inhaler aerosol, 80 mcg+4.5 mcg/dose, 160 mcg+4.5 mcg/dose, please visit the official website: grls.rosminzdrav.ru.

Quality control
at all stages of production